- 2 Risk factors for pneumococcal carriage in adults living with HIV on antiretroviral therapy in the
- 3 infant pneumococcal vaccine era in Malawi.
- 4

5 Authors

- 6 Deus Thindwa^{1,2*}, Thandie S Mwalukomo³, Jacquline Msefula², Kondwani C Jambo^{2,4}, Comfort
- 7 Brown², Arox Kamng'ona³, Charles Mwansambo⁵, John Ojal^{1,6}, Stefan Flasche¹, Neil French⁷, Robert
- 8 S Heyderman⁸, Todd D Swarthout^{2,8}.

- ¹⁰ ¹ Centre for the Mathematical Modelling of Infectious Diseases, Department of Infectious Disease
- 11 Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.
- ² Malawi-Liverpool-Wellcome Programme, Blantyre, Malawi.
- ³ School of Life Sciences and Allied Health Professions, Department of Biomedical Sciences,
- 14 Kamuzu University of Health Sciences, Blantyre, Malawi.
- ⁴ Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK.
- ⁵ Ministry of Health of Malawi, Lilongwe, Malawi
- ⁶ KEMRI-Wellcome Research Programme, Geographic Medicine Centre, Kilifi, Kenya.
- ⁷ Institute of Infection, Veterinary and Ecological Science, Department of Clinical Infection,
- 19 Microbiology, and Immunology, University of Liverpool, Liverpool, UK.
- ⁸ NIHR Mucosal Pathogens Research Unit, Research Department of Infection, Division of Infection
- 21 and Immunity, University College London, London, United Kingdom
- 22
- 23 Corresponding author
- 24 *Email:<u>deus.thindwa@lshtm.ac.uk</u>
- 25 <u>Phone: +265997788370</u>
- 26

2

27 Abstract

28 **Objective**

29 Adults living with HIV (ALWHIV) on antiretroviral therapy (ART) are at high risk of pneumococcal

- 30 carriage and disease. To help evaluate carriage risk in African ALWHIV in the infant pneumococcal
- 31 conjugate vaccination era, we assessed association between carriage and potential risk factors.

32

33 Methods

- 34 Nasopharyngeal swabs were collected from adults aged 18-40 years attending an ART clinic during
- 35 rolling, cross-sectional surveys in Blantyre, Malawi between 2015-2019. We fitted generalised
- 36 additive models to estimate the risk of sex, social economic status (SES), living with a child <5y, and
- 37 ART duration on carriage.
- 38

39 Results

40 Of 2,067 adults, median age was 33y (range 28-37), 1,427 (69.0%) were females, 1,087 (61.4%) were 41 in low-middle socio-economic-status (SES), 910 (44.0%) were living with a child <5y, and median 42 ART duration was 3.0 years (range 0.004-17). We estimated 38.2% and 60.6% reductions in overall 43 and vaccine-serotype carriage prevalence. Overall carriage was associated with low SES, living with a 44 child <5y and shorter duration on ART. By contrast, vaccine-type carriage was associated with living 45 without a child <5y and male sex.</p>

46

47 Conclusion

48 Despite temporal reductions in overall and vaccine-serotype carriage, there is evidence of incomplete

- 49 VT indirect protection. A targeted-vaccination campaign should be considered for ALWHIV, along
- 50 with other public health measures to further reduce vaccine-serotype carriage and therefore disease.
- 51
- 52 Key words: Pneumococcal carriage, pneumococcal conjugate vaccine, human immunodeficiency
- 53 virus, herd immunity, antiretroviral, risk factors, Malawi

54 Introduction

55	Streptococcus pneumoniae (the pneumococcus) is a common coloniser of the human nasopharynx,
56	particularly in young children and populations with human immunodeficiency virus (HIV) ¹ .
57	Pneumococcal colonisation is a necessary prerequisite for transmission and the development of
58	disease, including otitis media, sinusitis, pneumonia, meningitis, and bacteraemia ² . The
59	pneumococcus is associated with a large burden of disease in adults living with HIV (ALWHIV)
60	compared to adults without HIV $^{3-5}$. Adult HIV prevalence remains high (>10%) in many sub-Saharan
61	African countries, with Malawi reporting a national prevalence of 10.6% ⁶⁻⁸ . The use of antiretroviral
62	therapy (ART) has substantially increased survival and reduced the incidence of invasive
63	pneumococcal disease (IPD) ⁹ . However, despite more than 85% of ALWHIV in Malawi receiving
64	ART ¹⁰⁻¹² , ALWHIV remain at greater risk of IPD than adults without HIV ³ .
65	
66	Pneumococcal conjugate vaccines (PCVs) are widely used in infant schedules in low- and middle-
67	income countries (LMICs), generally targeting the most commonly invasive serotypes in this age
68	group ¹ . To date, in contrast to high-income settings, immunisation of vulnerable adults with
69	pneumococcal vaccines has not been adopted in most LMICs ¹³ . In November 2011, Malawi
70	introduced the 13-valent PCV (PCV13) into the national Expanded Program on Immunisation (EPI)
71	using a three-primary-dose schedule without booster (3+0; one dose at 6, 10 and 14 weeks of age).
72	Despite nearly 10 years of >80% PCV13 three-dose coverage among age-eligible children, there is
73	evidence of a sub-optimal reduction in both vaccine-serotype (VT) carriage prevalence and VT-IPD
74	incidence in children and ALWHIV in Malawi ^{14–16} . Similar evidence of residual VT carriage
75	prevalence is also reported in the Gambia and Mozambique after 5 and 2 years of implementation,
76	respectively, ¹⁷ despite both countries also reporting >80% PCV three-dose coverage under a 3+0
77	vaccine schedule ^{18,19} . There is increasing evidence that the indirect protection (i.e. herd immunity)
78	offered by an infant PCV against VT carriage, especially in ALWHIV, is sub-optimal ^{14,18} .
79	

4

80	The most effective strategy to reduce residual VT-IPD burden in ALWHIV depends on the factors
81	shaping VT carriage and disease risk. Before introducing infant PCV in Malawi and South Africa, risk
82	factors for IPD in ALWHIV included younger age, female sex, cotrimoxazole resistance, underlying
83	medical conditions and living in a densely populated area ^{3,4} . On the other hand, risk factors for
84	carriage of any pneumococcal serotype included exposure to infants exposed to HIV 20,21, low socio-
85	economic status (SES), high density living in housing with inadequate ventilation and with intense
86	social contacts ^{22–25} . Moreover, among Malawian ALWHIV, the overall (VT and non-VT [NVT])
87	carriage prevalence was found to be higher in those on ART than not on ART ^{26,27} .
88	
89	In the PCV era, however, there are important information gaps in our understanding of the relative
90	importance of of key factors for pneumococcal carriage and disease among ALWHIV. These include
91	duration on ART, PCV vaccination status among children in the household, and SES. Following our
92	recent data from Blantyre, Malawi showing high residual VT carriage and its determinants in PCV13-
93	vaccinated and unvaccinated children and in ALWHIV ^{15,16} , we extend the analysis to identify age-
94	and time-dependent risk factors for pneumococcal carriage in ALWHIV on ART using generalised
95	additive modelling.
96	

97 Methods

98 Study design

99 Blantyre is located in the southern region of Malawi spanning 2,025 km², with an urban (population

100 density 3,334/km²) and rural (253/km²) population of approximately 800,000 and 451,000 people,

101 respectively. ²⁸. As described elsewhere in more detail¹⁵, rolling, prospective cross-sectional

102 pneumococcal nasopharyngeal (NP) carriage surveys were conducted between 29 June 2015 and 9

- 103 August 2019 in Blantyre to investigate the change over time of pneumococcal colonisation in
- 104 ALWHIV on ART. The majority (98.6%) of sampled individuals were on a first line ART regimen
- 105 containing either i) Zidovudine, Lamivudine and Efavirenz, ii) Tenofovir, Lamivudine and Efavirenz
- 106 or iii) Tenofovir, Lamivudine and Nevirapine²⁹. Eight pneumococcal carriage surveys (each

5

107	approximately 6 months in	n duration) were conducted	l from 3.6 to 7.9 years after infant PC	V13
-----	---------------------------	----------------------------	---	-----

- 108 introduction into the EPI schedule. ALWHIV aged 18-40 years were recruited from the Queen
- 109 Elizabeth Central Hospital (QECH) ART clinic in Blantyre using a systematic sampling approach.
- 110 Exclusion from the study included being currently on treatment for tuberculosis, hospitalisation within
- 111 two weeks of recruitment and previously enrolled in the survey.
- 112

113 Nasopharyngeal sample collection and processing

- 114 An NP swab sample was collected from each participant and processed at the Malawi-Liverpool-
- 115 Wellcome Programme laboratory, co-located to QECH, to ascertain the presence of pneumococci.
- 116 Samples were collected and processed according to World Health Organisation guidelines ³⁰.
- 117 Serotyping was done using latex agglutination, based on picking a single colony, to identify serotypes
- 118 targeted by PCV13 (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F). Non-typeable and NVT
- 119 isolates were both classified as NVT. Pneumococcal carriage dynamics were further evaluated using
- 120 DNA microarray techniques, a technique which, in the case of co-carriage of multiple pneumococcal
- 121 serotypes, differentiates all individual serotypes and reports relative abundance of each serotype in
- 122 carriage ^{31,32}. Microarray was implemented only in surveys 1 through 4 and with samples having
- 123 latex-confirmed pneumococcal carriage. Further details of sample processing has been reported earlier
- 124

15,32

125

126 Data collection and analysis

127 Participant data collected at recruitment included age, sex, cohabitation with a child <5y (Yes/No),

social economic status (SES), duration of ART use, CD4+ T-cell count, current ART regimen and

129 cotrimoxazole use. A multiple imputation random forest-based method, using MissForest R package

- ³⁴, was conducted to impute 1 (0.0005%), 297 (14.4%), and 537 (26.0%) missing data points on
- 131 cohabitation with a child <5y, SES, and duration of ART use, respectively. Though reported in the
- descriptive analysis, CD4+ cell count was excluded from model-based analyses because 46.0% of its
- 133 data points were missing, a proportion above the acceptable standard threshold for imputation 34 .

134	Duration on ART was not used as a continuous variable because of data sparsity in age- or time-
135	stratified analyses but was categorised as short (<3 years) or long (\geq 3 years) duration based on (1) a
136	previous study in rural Malawi which showed strong evidence of high pneumococcal carriage during
137	the first 2 years of ART use ²⁶ , and (2) the median value of ART duration in this study.
138	
139	Individual fitted carriage prevalence estimates were categorised into 18-24y, 25-29y, 30-34y, and 35-
140	40y age groups reflecting their distinct IPD incidence ³ . Time was stratified into year of survey
141	initiation (2015, 2016, 2017, 2018 and 2019). In Malawi, pneumococcal carriage prevalence is usually
142	higher in the cold (May-August) and hot (September-November) seasons as compared to the rainy
143	season (December-April) ²⁶ . Thus, seasonality in carriage was captured using an indicator variable
144	with values ranging from January to December based on the month of NP sample collection.
145	
146	Generalised additive modelling framework
147	We used a generalised additive modelling (GAM) framework to fit to age- and time-specific
148	trajectories of pneumococcal carriage, and allow flexibility in capturing nonlinear carriage dynamics.
149	In brief, we used penalised B splines (P-splines) for the age and time spline smoothers to avoid knot
150	selections which usually introduce under- and over-fitting biases when trading-off model fit to the
151	data and the smoothness of the curve ³⁵ . A penalized log-likelihood maximization was used to fit a
152	non-parametric binomial model with complementary log-log link function defined by log-hazard of
153	carriage as a function of the risk factors and a spline in age and time. No time-series autocorrelation
154	structure was included in the model fits because ALWHIV were independently sampled without
155	replacement and with no evidence to suggest strong autocorrelation across time. Thus, the rolling,
156	prospective cross-sectional carriage samples and model residuals were assumed to be serially
157	independent.
158	

159 Age- and time-dependent carriage prevalence estimation

160 We modelled age- and time-dependent carriage trajectories separately for overall (VT+NVT) and VT 161 carriage as outcome variables for a set of potential risk factors. Due to reported poor immunogenicity and effectiveness of PCV13 against serotype 3^{36,37}, we also modelled VT carriage without serotype 3 162 163 (VT-st3) to explore changes in carriage prevalence. A model with age and time smoothers and 164 potential risk factors including sex, seasonality, duration on ART, cohabitation with a child <5 years 165 old, and SES were fitted to the carriage data to estimate the overall or VT carriage prevalence and risk 166 factor-specific effects on carriage prevalence dynamics. 167 A 'gam' function in the 'mgcv' R package facilitated model fitting ³⁸, based on a model formulated as 168 $g(P(Y_i = 1 | a_i, t_i)) = g(\pi(a_i, t_i)) = \eta(a_i, t_i)$, where Y_i is a binomial outcome on whether an 169 170 individual i is carrying pneumococcus (1) or not (0); g is the complementary log-log link function; 171 $\pi(a_i, t_i)$ is the carriage prevalence estimate for individuals of age (a_i) at time (t_i) ; $\eta(a_i, t_i)$ is a 172 nonparametric linear predictor as function of individual age and time, and a set of risk factors. The 173 linear predictor on a predictor scale is further expanded using the equation $\eta(a_i, t_i) = \beta_0 + \sum_k \beta_k G_i + te(a_i) + te(t_i)$, where β_0 is a model intercept, G_i refers to individual risk 174

175 factor category, β_k is the risk factor coefficient, $te(a_i)$ and $te(t_i)$ denote tensor product P-spline of

176 predictor age (a_i) and time (t_i) .

177

The relative difference in carriage prevalence was computed by subtracting the GAM carriage
prevalence estimate for each age or time category from the reference category and then dividing the
difference by the reference category and then multiplying by 100%. The 95% confidence interval
(95% CI) of the relative difference was estimated using

182 $(\rho + 1) * [1 \pm 1.96 * \sqrt{\delta_1^2 + \delta_2^2 - (1.96^2) * \delta_1^2 * \delta_2^2} / (1 - 1.96 * \delta_1^2)] - 1$, where ρ is the relative

183 difference, δ_1 and δ_2 are the coefficient variations of the reference and comparator categories,

184 respectively, and coefficient variation being standard deviation divided by the observed mean ³⁹.

185 GAMs with and without interactions between age group or time and each independent risk factor on

8

186	the overall and VT	carriage prevalence	e were fitted and con	npared using Akai	ke information criterion

- 187 (AIC), and results of these tests are numerically presented in S1 Table. Given the model
- 188 complexities, sensitivity analyses assessed factors that may affect carriage estimates which included
- 189 the impact on carriage of individual age group or survey, serotyping method, carriage autocorrection,
- 190 model formulation and spline type. Detailed sensitivity methods and results are presented in
- 191 Supplementary Material (S1 Text and S2 Text). Analyses were conducted in R v4.1.1 ⁴⁰, with
- 192 statistical significance set at p < 0.05, and the code is publicly shared via GitHub⁴¹.

193

194 Ethical approval

- 195 Ethical approval for this study was granted by the College of Medicine Research Ethics Committee,
- 196 Kamuzu University of Health Sciences (P.02/15/1677), the Liverpool School of Tropical Medicine
- 197 Research Ethics Committee (14.056) and the London School of hygiene and Tropical Medicine
- 198 (26839). Individual written informed consent, including consent for publication, was obtained from
- 199 each participant prior to study recruitment.
- 200

201 **Results**

202 **Descriptive analysis**

- A total of 2,067 ALWHIV aged 18-40y were enrolled in the study between 29 June 2015 and 9
- August 2019. Among adults with non-missing data, 1,427 (69.0%, n=2,067) were females, 413
- 205 (23.3%, n=1,770) and 674 (38.1%, n=1,770) were from low and middle SES households, respectively,
- 1,156 (56.0%, n=2,066) were not living with a child <5y, 1,772 (98.5%, n=1,799) were on one of
- 207 Malawi's first-line ART regimens, and 2,010 (97.2%, n=2,067) were using prophylactic
- 208 cotrimoxazole at recruitment. The median age was 33y (IQR: 28-37, n=2,067), median CD4+ count
- was 252 cells/mm³ (IQR: 138-443, n=1,117), and median duration on ART at the time of study
- 210 recruitment was 3.0 years, (range: 0-17, n=1,530) (Fig. 1).

9



- 213 identified. Survey-aggregated data showed that carriage prevalence was 552 (26.7%, n=2,067) for
- 214 overall (VT+NVT) and 232 (11.2%, n=2,067) for VT. It also showed that overall and VT carriage
- 215 prevalence was 537 (37.7%, n=1,427) and 155 (10.9%, n=1,427) among females, 247 (38.6%, n=640)
- 216 and 77 (12.0%, = 640) among males, 195 (47.2%, n=413) and 59 (14.3%, n=413) in low SES, 276
- 217 (40.9%, n=674) and 85 (12.6%, n=674) in middle SES and 243 (35.6%, n=683), 73 (10.7%, =683) in
- 218 high SES households, 361 (39.7%, n=910) and 111 (12.2%, n=910) in adults living with a child <5y,
- 219 423 (36.6%, n=1,156) and 121 (10.5%, n=1,156) in adults living without a child <5y, 682 (38.5%,
- 220 n=1,778) and 199 (11.2%, n=1,778) in adults on a first-line ART regimen, 9 (33.3%, n=27) and 3
- 221 (11.1%, n=27) in adults on second-line ART regimen, 767 (38.1%, n=2,010) and 228 (11.3%,
- 222 n=2,010) in adults taking cotrimoxazole, 17 (29.8%, n=57) and 4 (7.0%, n=57) in adults not taking
- cotrimoxazole (Fig 1).



225

Figure 1. Demographics and clinical characteristics of participants using aggregated data across eight
surveys. (A) Frequency of each VT in carriage; insert shows frequency of VT, NVT and no carriage.
(B) Number of adults in each annual age per survey with circle size proportional to total sample size.
The number of adults with VT, NVT, and no carriage living with (C) varying number of children <5
years or (D) across survey years. Notched box plots by serotype group representing participant

10

- 231 distribution by (E) age, (F) duration on ART and (G) CD4+ count. Proportion of serotype group by
- 232 (H) sex, (I) social economic status, (J) ART regimen and (K) Cotrimoxazole use.

233

234 Age- and time-dependent carriage prevalence estimates

- 235 Our GAM predicted a significant reduction in overall and VT carriage prevalence with increasing age
- and time. Among older age categories, overall carriage prevalence was lower than the reference
- 237 younger adults aged 18-24y, with greatest reduction in adults aged 30-34y (-22.8%, 95%CI -34.1, -
- 238 10.4). Likewise, VT carriage prevalence was lower in older than younger adults, with highest
- reduction in adults aged 30-34y (-45.1%, 95% CI -61.8, -25.6). Across time, we estimated lower
- 240 overall (-38.2%, 95% CI -51.7, -23.6) and VT (-60.6%, 95% CI -79.1, -39.2) carriage prevalence in
- 241 2019 compared to 2015. In a sub-analysis, serotype 3 made up 22.6-34.7% (across age groups) and
- 242 18.9-38.2% (across time) of VT carriage prevalence (Table 1; Fig. 2).
- 243

Table 1. Age- and ti	me-dependent o	overall and VT	carriage prevalence	, and relative differen	ice in fitted carriage	e prevalence among ALWI	HIV on ART, 2015-2019
in Blantyre, Malawi							

	Observed overall	Modelled [‡] overall	Relative difference [†] in	Observed VT	Modelled [‡] VT carriage	Relative difference [†] in
	carriage	carriage prevalence	overall carriage	carriage	prevalence	VT carriage
	-		-	-	-	-
	n/N (%)	(95%CI)	(95%CI)	n/N (%)	(95%CI)	(95%CI)
Age (years)						
18-24	144/310 (46.5)	49.2 (40.9, 58.0)	Reference	50/310 (16.1)	19.5 (13.0, 28.6)	Reference
	· /			. ,		
25-29	120/337 (35.6)	40.0 (33.8, 46.8)	-18.7 -32.3, -4.1)	32/337 (9.5)	12.4 (8.7, 17.6)	-36.4 (-58.0, -11.4)
	· /		, , ,	. ,		
30-34	213/585 (36.4)	38.0 (32.1, 44.5)	-22.8 (-34.1, -10.4)	63/585 (10.8)	10.7 (7.4, 15.1)	-45.1 (-61.8, -25.6)
	· · /			. ,		
35-40	307/835 (36.8)	38.0 (31.8, 45.0)	-22.8 (-33.3, -11.2)	87/835 (10.4)	11.8 (8.1, 17.1)	-39.4 (-55.9, -19.9)
	(,					(, , , , , , , , , , , , , , , , , , ,
Year						
2015	114/265 (43.0)	45.0 (37.4, 53.3)	Reference	40/265 (15.1)	17.0 (11.4, 24.8)	Reference
				. ,		
2016	218/494 (44.1)	44.7 (38.0, 52.0)	-0.7 (-16.3, 16.8)	67/494 (13.6)	15.3 (10.6, 21.8)	-10.0 (-37.7, 24.4)
			···· (··· , ··· ,			
2017	226/561 (40.3)	41.6 (35.2, 48.6)	-7.6 (-22.1, 8.7)	69/561 (12.3)	13.1 (9.1, 18.8)	-22.9 (-46.9, 6.8)
	()	,,		0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		(````,```,```
2018	156/450 (34.7)	34.8 (29.0, 41.3)	-22.7 (-36.2, -7.7)	41/450 (9.1)	8.8 (5.9, 12.9)	-48.2 (-67.3, -25.3)
		(->+++)				
2019	70/297 (23.6)	27.8 (22.0, 34.6)	-38.2 (-51.7, -23.6)	15/297 (5.1)	6.7 (4.2, 10.6)	-60.6 (-79.1, -39.2)
-			(,)			····· (·····, •/••••)

‡ Carriage prevalence was modelled by fitting a GAM to individual carriage trajectories adjusting for risk factors as described in Methods

† Relative difference was computed by subtracting a GAM carriage prevalence estimate from the reference category and then dividing the difference by the

reference category and then multiplying by 100%.



ALWHIV - adults living with human immunodeficiency virus.

ART - Antiretroviral therapy

95%CI - 95% confidence interval.

Values in bold are statistically significant (p < 0.05).





Figure 2. Observed and fitted pneumococcal carriage prevalence curves using data from rolling,

prospective cross-sectional surveys in Blantyre, Malawi 2015-19. Number of carriage samples per age group between 18 to 40 years (y) and survey time from 2015 to 2019 represented by open circles radius proportion to total sample size with corresponding confidence intervals (vertical lines). P-spline GAM fitted lines and confidence intervals (ribbons) for the (A) age- and (B) time-dependent carriage prevalence stratified by overall carriage, vaccine serotypes (VT) carriage and VT carriage without serotype 3 (VT-st3).

253

254 Factors associated with overall carriage prevalence

255 Overall carriage prevalence was only independently associated with SES, with adults in low SES

having 22% higher overall carriage than those in high SES (21.9, 95% CI 1.6, 43.7). In a sub-analysis

with age and time-stratification, our model predicted that being a younger (18-24y) adult in low SES

12

258	or living with	a child aged < 5	y was significantl	y associated with higher of	overall carriage prevalence.
			J	,	

- 259 Significant associations with low SES and shorter ART duration were also seen with overall carriage.
- 260 Overall carriage prevalence in younger adults was significantly higher by 42% for those in low vs
- high SES (41.8, 95%CI 12.5, 74.0) and 27% for those living with vs those living without a child <5y
- 262 (27.2, 95%CI 0.4, 57.4). Temporally, overall carriage prevalence was persistently higher by 50% in
- 263 2018 (49.5, 95% CI 13.4, 89.8) and 84% in 2019 (83.6, 95% CI 20.5, 167.4) in adults in the low vs
- high SES, and higher by 35% in 2015 (35.4, 95% CI 0.9, 77.2) and 131% in 2019 (130.8, 95% CI 43.2,
- 265 255.4) in adults with shorter vs longer duration on ART (Table 2, Fig. 3, S1 Table).
- 266

267 Factors associated with VT carriage prevalence

- 268 Sex, SES, ART duration and living with a child <5y were not significantly associated with VT
- 269 carriage prevalence. However, with age- and time-stratification, our model of VT carriage outcome
- 270 predicted that being a younger (18-24y) or older (35-40y) adult living without a child <5y or being
- 271 older male significantly increased VT carriage prevalence. Temporally, living without a child <5y
- 272 remained a significant predictor of higher carriage prevalence in 2019. Living without vs with a child
- 273 <5y significantly increased VT carriage prevalence by 67% in younger adults 67.1 (95% CI 10.7,
- 274 140.5) and 41.0% in older adults (95% CI 1.5, 88.6). VT carriage prevalence was significantly higher
- 275 in older males than females (50.0, 95%CI 7.2, 100.7; Table 2, Fig. 3, S1 Table).
- 276

Table 2. Risk factors for age and time dependent overall and VT with serotype 3 carriage prevalence, and the relative differences in the flued carriage prevalence between the reference group and comparative groups among ALWHV on ART, 20 2019 in Blanytre, Malawi. Risk factors for age and time dependent overall and VT with serotype 3 carriage prevalence (95%CT) % Relative differences' in age dependent carriage prevalence (95%CT) % Relative differences' in time-dependent carriage prevalence (95%CT) Risk factors (95%CT) 18.24y 25.29y 30-34y 35-40y 2015 2016 2017 2018 Correal carriage -4.8 (200, 13.5) -18.1 (-557, 17.1) 16.3 (-150, 57.2) 19.0 (-85, 52.9) -10.3 (-255, 6.8) -13.5 (-35, 7.42) -10.4 (-35, 7.42) 19.6 (-3.4, 80.4) 83.6 (20.5, 1 Low vs High SES 21.9 (1.6, 4.33) 41.8 (12.5, 7.40) 2.1 (-20.0, 32.9) 22.2 (-2.8, 49.2) 19.9 (-1.8, 42.9) 10.5 (-10.2, 52.2) 19.3 (-5.4, 45.8) 2.0 (-0.1, 55.2) 49.5 (1.4, 4.9, 4.9) 16.8 (-20.5, 1.2) 4.8 (-40.9, 1.5) -1.5 (-3.1, 5.1) 1.9 (-20.8, 2.8, 4.4, 7 (-23.9, 4.0.6) 4.4 (-15.7, 20.8) 19.9 (-4.4, 1.8) 5.4 (0.9, 77.2) 3.9 (-15.7, 2.5.3) -0.7 (-1.9, 1.1.99 2.6 (-2.4, 1.6, 1.4) 19.8 (-4.2, 9.2, 1.5) 4.8 (-4.9, 5.7.3) 1.1 (-7.4, 2.9, 4.9, 4.3, 4.7 (-2.3, 1.4.1, 4.9, 7	abb 2. Risk factors for age- and time-dependent overall and VT with servicye 3 carriage prevalence, edges(C) % Relative difference* in time-dependent carriage prevalence (95%C) 109 in Blantyre, Malawi.	time-dependent ov erall % relative ference [†]	verall and VT with ser % Relative difference	rotype 3 carriage preva	alence, and the relative	differences in the fitt	ed carriage prevalence	between the reference	group and comparativ	a groups among ALW	
90 Pin Bianyen, Mainer Angenese A difference ¹ (afference ¹) (afference ¹) (afferenc	Momental Status Normal % relative Section of the ends in use dependent carrings prevalence (9%C) Stelative difference in time dependent carrings prevalence (9%C) bisk factors difference in difference in age dependent carrings prevalence (9%C) Stelative difference in time dependent carrings prevalence (9%C) 2016 2017 2018 2018 breatl carrings difference in the din the difference in the difference in the difference in the diffe	erall % relative ference [†]	% Relative difference						group und computation	e groups among ALW	HIV on ART, 201
Overall % relative difference ¹ (95%CI) % Relative difference ¹ in age-dependent carriage prevalence (95%CI) % Relative difference ¹ in time-dependent carriage prevalence (95%CI) verall carriage 18-24y 25-29y 30-34y 35-40y 2015 2016 2017 2018 male v male -4.8 (-209, 13.5) -18.1 (-357, 1.7) 16.3 (-15.9, 57.2) 19.0 (+8.5, 52.9) -10.3 (-25.5, 6.8) -13.5 (-35.5, 12.7) -6.1 (-23.9, 14.2) 7.1 (-14.5, 32.5) -12.9 (-33.8, 12.2) 16.8 (-67.4, aw vs High SES 21.9 (1.6, 43.7) 41.8 (12.5, 74.0) 2.1 (-26.0, 32.9) 2.2 (-2.8, 49.2) 19.9 (-1.8, 42.9) 16.5 (-16.2, 52.2) 19.3 (-5.4, 45.8) 26.7 (-0.1, 55.2) 49.5 (13.4, 89.8) 83.6 (20.5, 1 10.8 (-43.7, 45.8) RT <3 vs ART >3 11.5 (-6.7, 31.5) 1.9 (-20.8, 28.4) 4.7 (-23.9, 40.6) 4.4 (-15.7, 26.8) 19.9 (-0.4, 41.8) 35.4 (0.9, 77.2) 3.9 (-15.7, 25.3) -0.7 (-1.9, 4.19.9) 26.2 (-4.1, 61.4) 13.08 (-43.2, 44.7) -7.6 (-41.8) Tarriage	Overall & relative difference" (9%CI) % Relative difference" in age-dependent curringe prevalence (0%CI) % Relative difference" in time-dependent curringe prevalence (0%CI) verall carringe Image dependent curringe prevalence (0%CI) % Relative difference" in time-dependent curringe prevalence (0%CI) verall carringe Image dependent curringe prevalence (0%CI) % Relative difference" in time-dependent curringe prevalence (0%CI) verall carringe Image dependent curringe prevalence (0%CI) % Relative difference" in time-dependent curringe prevalence (0%CI) verall carringe Image dependent curringe prevalence (0%CI) % Relative difference" in time-dependent curringe prevalence (0%CI) verall carringe Image dependent curringe prevalence (0%CI) % Relative difference" in time-dependent curringe prevalence (0%CI) verall carringe Image dependent curringe prevalence (0%CI) % Relative difference" in time-dependent curringe prevalence (0%CI) remaine veralle carringe 115 (-67.31.5) 148 (125.740) 2.1 (260.32.7) 2.2 (2.2.8.18.0) 3.2 (4.9.2.8.18.0) 3.7 (19.7.2.8.0) 3.8 (4.9.4.9.17) 3.8 (4.9.4.9.17) 3.8 (4.9.4.9.17) 3.8 (4.9.4.9.17) 3.8 (4.9.4.9.17) 3.8 (4.9.4.9.17) 3.8 (4.9.4.9.17) 3.8 (4.9.4.9.17) 3.8 (4.9.4.9.17) 3.8 (4.9.4.9.17) 3.8 (4.9.4.9.17)<	erall % relative ference [†]	% Relative difference								
isk factors ist factors i	isk factors difference!	ference [†]		ce [†] in age-dependent c	arriage prevalence (95	% CI)	% Relative difference	e [†] in time-dependent c	arriage prevalence (95	5%CI)	
Overall carriage Image Image <th>benefit carriage Inc. Inc.<th>5%CI)</th><th>18-24y</th><th>25-29y</th><th>30-34y</th><th>35-40y</th><th>2015</th><th>2016</th><th>2017</th><th>2018</th><th>2</th></th>	benefit carriage Inc. Inc. <th>5%CI)</th> <th>18-24y</th> <th>25-29y</th> <th>30-34y</th> <th>35-40y</th> <th>2015</th> <th>2016</th> <th>2017</th> <th>2018</th> <th>2</th>	5%CI)	18-24y	25-29y	30-34y	35-40y	2015	2016	2017	2018	2
temale wale 4.8 (209, 13.5) $1.8.1$ (357, 1.7) 16.3 (15.9, 57.2) 19.0 (8.5, 52.9) 10.3 (255, 6.8) 13.5 (355, 12.7) 6.1 (23.9, 14.2) 7.1 (14.5, 32.5) 12.9 (33.8, 12.2) 16.8 (27.4, 39.8) $xw v s High SES$ 21.9 (1.6, 43.7) 41.8 (12.5, 74.0) 2.1 (260, 32.9) 22.2 (2.8, 9.2) 19.9 (1.4, 18.9) 35.4 (0.9, 77.2) 3.9 (15.7, 25.3) -0.7 (19.4, 19.9) 26.2 (2.1, 61.4) 130.8 (43.2, 2.2) With vs without child <5y	windle vs male 4.8 (-20,9,13.5) -18.1 (-35.7,1.7) 16.3 (-15.9, 57.2) 19.0 (-8.5, 52.9) -10.3 (-25.5, 6.8) -13.5 (-35.5, 12.7) 6.1 (-23.9, 14.2) 7.1 (-14.5, 32.5) -12.9 (-3.3.8, 12.2) 16.8 (-27.4, ' ww vs High SES 21.9 (16.43.7) 11.8 (12.5, 74.0) 2.1 (-26.0, 32.9) 22.2 (-2.8, 49.2) 19.9 (-18, 42.9) 16.5 (-16.2, 52.2) 19.3 (-5.4, 45.8) 26.7 (-01, 55.2) 49.5 (13.4, 89.8) 83.6 (20.5, 10.1) RT Arx vs High SES 11.5 (-6.7, 31.5) 1.9 (-20.8, 28.4) 4.7 (-23.9, 40.6) 4.4 (-15.7, 26.8) 19.9 (-0.4, 41.8) 35.4 (0.9, 77.2) 3.9 (-15.7, 25.3) -0.7 (-19.4, 19.9) 26.2 (-4.1, 61.4) 130.8 (-43.2, 27.4) vin vs without chid 9.7 (-0.8, 29.1) 27.2 (0.4, 87.4) 2.6 (-22.9, 31.8) 0.3 (-19.5, 22.1) 8.9 (-92, 28.5) 8.7 (-18.4, 39.5) 11.1 (-17.9, 22.2) 7.4 (-12.4, 29.4) 13.8 (-14.3, 44.7) -7.6 (-41.8, 3.2) umale vs male -18.6 (-64.9, 53.7) -16.6 (-51.2, 28.0) 26.5 (-42.8, 14.60) -5.1 (-47.8, 59.1) 333 (-55.6 (-58.6) -11.7 (-47.0, 94.6) 32 (-48.7, 47.9) 17.6 (-48.2, 80.9) 37.3 (-39.2, 13.2) 53.1 (-48.0, 27.2) ww s High SES 6.0 (-61.0, 91.2)										
ow wight SES 219 (16, 43.7) 41.8 (12.5, 74.0) 2.1 (-26.0, 32.9) 22.2 (-2.8, 49.2) 19.9 (-1.8, 42.9) 16.5 (-16.2, 52.2) 19.3 (-5.4, 45.8) 26.7 (-0.1, 55.2) 49.5 (13.4, 89.8) 83.6 (20.5, 1.1, 1.1, 1.1, 1.1, 1.1, 1.1, 1.1, 1	ow willight SES 21.9 (1,6,4,3.7) 41.8 (12,5,7.40) 2.1 (-26.0, 32.9) 22.2 (-2.8, 49.2) 19.9 (-1.8, 42.9) 16.5 (-16.2, 52.2) 19.3 (-5.4, 45.8) 26.7 (-0.1, 55.2) 49.5 (13.4, 89.8) 83.6 (20.5, 11.1, 10.1, 1	4.8 (-20.9, 13.5)	-18.1 (-35.7, 1.7)	16.3 (-15.9, 57.2)	19.0 (-8.5, 52.9)	-10.3 (-25.5, 6.8)	-13.5 (-35.5, 12.7)	-6.1 (-23.9, 14.2)	7.1 (-14.5, 32.5)	-12.9 (-33.8, 12.2)	16.8 (-27.4, 7
RT <3y vs ART \geq 3y 11.5 (-6.7, 31.5) 1.9 (-20.8, 28.4) 4.7 (-23.9, 40.6) 4.4 (-15.7, 26.8) 19.9 (-0.4, 41.8) 35.4 (0.9, 77.2) 3.9 (-15.7, 25.3) -0.7 (-19.4, 19.9) 26.2 (-4.1, 61.4) 130.8 (43.2, 2.7) /ith vs without child <5y	$RT < 3y vs ART \ge 3y$ $11.5 (-6.7, 31.5)$ $19 (-20.8, 28.4)$ $4.7 (-23.9, 40.6)$ $4.4 (-15.7, 26.8)$ $199 (-0.4, 41.8)$ $35.4 (0.9, 77.2)$ $3.9 (-15.7, 25.3)$ $-0.7 (-19.4, 19.9)$ $2.6 (-2.4, 1.6.1.4)$ $130 (43.2, 26.7)$ $7.6 (-4.1.8, 1.2.7)$ $7.7 (-4.1.8, 1.2.7)$ $7.6 (-4.1.8, 1.2.7)$ $7.6 (-4.1.8, 1.2.7)$	21.9 (1.6, 43.7)	41.8 (12.5, 74.0)	2.1 (-26.0, 32.9)	22.2 (-2.8, 49.2)	19.9 (-1.8, 42.9)	16.5 (-16.2, 52.2)	19.3 (-5.4, 45.8)	26.7 (-0.1, 55.2)	49.5 (13.4, 89.8)	83.6 (20.5, 16
With vs without child $<$ 5y9.7 (\cdot 0.8, 29.1)27.2 (\cdot 0.4, 57.4)2.6 (\cdot 22.9, 31.8)0.3 (\cdot 19.5, 22.1)8.9 (\cdot 9.2, 28.5)8.7 (\cdot 18.4, 39.5)1.1 (\cdot 17, 9, 22.2)7.4 (\cdot 12.4, 29.4)13.8 (\cdot 14.3, 44.7)-7.6 (\cdot 41.8, 7.6	Vith vs without child <5y9.7 ($-0.8, 29.1$) 272 ($0.4, 57.4$) 2.6 ($-22.9, 31.8$) $0.3 (\pm 195, 22.1)$ $8.9 (+9.2, 28.5)$ $8.7 (\pm 18.4, 39.5)$ $1.1 (\pm 17.9, 22.2)$ $7.4 (\pm 2.4, 29.4)$ $13.8 (\pm 4.3, 44.7)$ $7.7.6 (\pm 1.8.5, 20.4)$ T carriageImage: Image: Im	11.5 (-6.7, 31.5)	1.9 (-20.8, 28.4)	4.7 (-23.9, 40.6)	4.4 (-15.7, 26.8)	19.9 (-0.4, 41.8)	35.4 (0.9, 77.2)	3.9 (-15.7, 25.3)	-0.7 (-19.4, 19.9)	26.2 (-4.1, 61.4)	130.8 (43.2, 25
T carriage Image: Constraint of the state of the	T carriage Image: Control of the state of the state of the reference category from the comparator category and then dividing the absolute difference by the reference category then multiplied by 100%. Relative difference was computed by subtracting a GAM carriage prevalence estimate of the reference category from the comparator category and then dividing the absolute difference by the reference category then multiplied by 100%. RC (44, 9, 10) State (45, 12, 28, 6) State (55, 12, 28, 6) State (9.7 (-0.8, 29.1)	27.2 (0.4, 57.4)	2.6 (-22.9, 31.8)	0.3 (-19.5, 22.1)	8.9 (-9.2, 28.5)	8.7 (-18.4, 39.5)	1.1 (-17.9, 22.2)	7.4 (-12.4, 29.4)	13.8 (-14.3, 44.7)	-7.6 (-41.8, 3
$-18.6(-64,9,53.7)$ $-16.6(-51.2, 28.6)$ $26.8(-42.8, 146.6)$ $-5.1(-47.8, 59.1)$ $-33.3(-55.6, -5.8)$ $-21.4(-58.3, 31.3)$ $-18.0(-48.9, 22.5)$ $-13.3(-47.6, 33.1)$ $1.1(-54.4, 92.7)$ $40.3(-72.9, 33.1)$ ow vs High SES $6.0(-61.0, 91.2)$ $-26.5(-67.6, 19.6)$ $12.5(-46.6, 85.4)$ $23.8(-32.4, 90.8)$ $35.8(-14.5, 93.2)$ $17.7(-47.0, 94.6)$ $-3.2(-48.7, 47.9)$ $17.6(-38.2, 80.9)$ $37.3(-39.2, 133.2)$ $53.1(-48.0, 23.4)$ $ART < 3y$ vs $ART \ge 3y$ $0.0(-55.1, 77.4)$ $-14.5(-49.6, 32.3)$ $-15.3(-63.7, 65.3)$ $33.7(-19.3, 102.1)$ $-2.9(-36.4, 35.0)$ $32.7(-26.2, 114.5)$ $-6.9(-42.9, 36.2)$ $-21.9(-51.5, 13.6)$ $10.(-49.2, 67.6)$ $54.4(-53.7, 2.8)$ With vs without child $< 5y$ $33.1(-40.9, 142.5)$ $-40.2(-64.7, -9.9)$ $-6.6(-52.3, 54.3)$ $8.6(-36.6, 67.6)$ $-29.1(-52.8, -0.5)$ $7.7(-43.3, 73.9)$ $26.9(-21.2, 89.1)$ $50.4(-6.0, 125.0)$ $4.5(-55.1, 78.6)$ $-84.8(-108.2, -38.2)$ ART: Antiretroviral therapy, ALWHIV: adults living with human immunodeficiency virus, CI: confidence intervals, y: year, SES: Social Economic Status score based a possession index which is calculated as a sum of positive responses for house wavership of each of the fifteen different functioning items such as watch, radio, bank account, iron (charcoal), sewing machine (electric), mobile phone, CD player, fan	emale -18.6 (-649, 53.7) -16.6 (-51.2, 28.6) 26.8 (-42.8, 146.6) -5.1 (-47.8, 59.1) -33.3 (-55.6, -5.8) -21.4 (-58.3, 31.3) -18.0 (-48.9, 22.5) -13.3 (-47.6, 33.1) 1.1 (-54.4, 92.7) 40.3 (-72.9, 31.3) ow vs High SES 6.0 (-61.0, 91.2) -26.5 (-67.6, 19.6) 12.5 (-46.6, 85.4) 23.8 (-32.4, 90.8) 35.8 (-14.5, 93.2) 17.7 (-47.0, 94.6) -3.2 (-48.7, 47.9) 17.6 (-38.2, 80.9) 37.3 (-39.2, 13.2) 53.1 (-48.0, 22.5) virt vs without child <5y										
Now vs High SES $6.0(-61.0, 91.2)$ $-26.5(-67.6, 19.6)$ $12.5(-46.6, 85.4)$ $23.8(-32.4, 90.8)$ $35.8(-14.5, 93.2)$ $17.7(-47.0, 94.6)$ $-3.2(-48.7, 47.9)$ $17.6(-38.2, 80.9)$ $37.3(-39.2, 133.2)$ $53.1(-48.0, 2)$ ART $<3y$ vs ART $\geq 3y$ $0.0(-55.1, 77.4)$ $-14.5(-49.6, 32.3)$ $-15.3(-63.7, 65.3)$ $33.7(-19.3, 102.1)$ $-2.9(-36.4, 35.0)$ $32.7(-26.2, 114.5)$ $-6.9(-42.9, 36.2)$ $-21.9(-51.5, 13.6)$ $1.0(-49.2, 67.6)$ $54.4(-53.7, 2)$ With vs without child $<5y$ $33.1(-40.9, 142.5)$ $-40.2(-64.7, -9.9)$ $-6.6(-52.3, 54.3)$ $8.6(-36.6, 67.6)$ $-29.1(-52.8, -0.5)$ $7.7(-43.3, 73.9)$ $26.9(-21.2, 89.1)$ $50.4(-6.0, 125.0)$ $4.5(-55.1, 78.6)$ $-84.8(-108.2, -108.2, -108.2)$ Relative difference was computed by subtracting a GAM carriage prevalence estimate of the reference category from the comparator category and then dividing the absolute difference by the reference category then multiplied by 100%.ART: Antiretroviral therapy, ALWHIV: adults living with human immunodeficiency virus, CI: confidence intervals, y: year, SES: Social Economic Status score based a possession index which is calculated as a sum of positive responses for housewnership of each of the fifteen different functioning items such as watch, radio, bank account, iron (charcoal), sewing machine (electric), mobile phone, CD player, fan (electric), bednet, mattress, bed, bicycle, motorcycle, car, and television. MichMRT S were combined and named as high SES.	ow ws High SES $6.0(-61.0, 91.2)$ $-26.5(-67.6, 19.6)$ $12.5(-46.6, 85.4)$ $23.8(-32.4, 90.8)$ $35.8(-14.5, 93.2)$ $17.7(-47.0, 94.6)$ $-3.2(-48.7, 47.9)$ $17.6(-38.2, 80.9)$ $37.3(-39.2, 133.2)$ $53.1(-48.0, 22)$ uRT <3y vs ART $\geq 3y$ $0.0(-55.1, 77.4)$ $-14.5(-49.6, 32.3)$ $-15.3(-63.7, 65.3)$ $33.7(-19.3, 102.1)$ $-2.9(-36.4, 35.0)$ $32.7(-26.2, 114.5)$ $-6.9(-42.9, 36.2)$ $-21.9(-51.5, 13.6)$ $1.0(-49.2, 67.6)$ $54.4(-53.7, 25)$ Vith vs without child <5y	8.6 (-64,9, 53.7)	-16.6 (-51.2, 28.6)	26.8 (-42.8, 146.6)	-5.1 (-47.8, 59.1)	-33.3 (-55.6, -5.8)	-21.4 (-58.3, 31.3)	-18.0 (-48.9, 22.5)	-13.3 (-47.6, 33.1)	1.1 (-54.4, 92.7)	40.3 (-72.9, 31)
$RT < 3y vs ART \ge 3y$ $0.0 (-55.1, 77.4)$ $-14.5 (-49.6, 32.3)$ $-15.3 (-63.7, 65.3)$ $33.7 (-19.3, 102.1)$ $-2.9 (-36.4, 35.0)$ $32.7 (-26.2, 114.5)$ $-6.9 (-42.9, 36.2)$ $-21.9 (-51.5, 13.6)$ $1.0 (-49.2, 67.6)$ $54.4 (-53.7, 2)$ $Relative difference was computed by subtracting a GAM carriage prevalence estimate of the reference category from the comparator category and then dividing the absolute difference by the reference category then multiplied by 100%.$ $RT: Antiretroviral therapy, ALWHIV: adults living with human immunodeficiency virus, CI: confidence intervals, y: year, SES: Social Economic Status score based a possession index which is calculated as a sum of positive responses for house wnership of each of the fifteen different functioning items such as watch, radio, bank account, iron (charcoal), sewing machine (electric), mobile phone, CD player, fan (electric), bednet, mattress, bed, bicycle, motorcycle, car, and television. Micro and high SES were combined and named as high SES.$	$\frac{1}{4277} = \frac{1}{4277} = \frac{1}{4277} = \frac{1}{425} + \frac$	6.0 (-61.0, 91.2)	-26.5 (-67.6, 19.6)	12.5 (-46.6, 85.4)	23.8 (-32.4, 90.8)	35.8 (-14.5, 93.2)	17.7 (-47.0, 94.6)	-3.2 (-48.7, 47.9)	17.6 (-38.2, 80.9)	37.3 (-39.2, 133.2)	53.1 (-48.0, 22)
Vith vs without child <5y	Vith vs without child <5y	0.0 (-55.1, 77.4)	-14.5 (-49.6, 32.3)	-15.3 (-63.7, 65.3)	33.7 (-19.3, 102.1)	-2.9 (-36.4, 35.0)	32.7 (-26.2, 114.5)	-6.9 (-42.9, 36.2)	-21.9 (-51.5, 13.6)	1.0 (-49.2, 67.6)	54.4 (-53.7, 25
Relative difference was computed by subtracting a GAM carriage prevalence estimate of the reference category from the comparator category and then dividing the absolute difference by the reference category then multiplied by 100%. ART: Antiretroviral therapy, ALWHIV: adults living with human immunodeficiency virus, CI: confidence intervals, y: year, SES: Social Economic Status score based a possession index which is calculated as a sum of positive responses for house where ships of each of the fifteen different functioning items such as watch, radio, bank account, iron (charcoal), sewing machine (electric), mobile phone, CD player, fan (electric), bednet, mattress, bed, bicycle, motorcycle, car, and television. Mic nd high SES were combined and named as high SES.	Relative difference was computed by subtracting a GAM carriage prevalence estimate of the reference category from the comparator category and then dividing the absolute difference by the reference category then multiplied by 100%. ART: Antiretroviral therapy, ALWHIV: adults living with human immunodeficiency virus, CI: confidence intervals, y: year, SES: Social Economic Status score based a possession index which is calculated as a sum of positive responses for housel wnership of each of the fifteen different functioning items such as watch, radio, bank account, iron (charcoal), sewing machine (electric), mobile phone, CD player, fan (electric), bednet, mattress, bed, bicycle, motorcycle, car, and television. Midc nd high SES were combined and named as high SES. 277	.1 (-40.9, 142.5)	-40.2 (-64.7, -9.9)	-6.6 (-52.3, 54.3)	8.6 (-36.6, 67.6)	-29.1 (-52.8, -0.5)	7.7 (-43.3, 73.9)	26.9 (-21.2, 89.1)	50.4 (-6.0, 125.0)	4.5 (-55.1, 78.6)	-84.8 (-108.2, -5
		ed by subtracting a VHIV: adults living ifferent functioning named as high SE	GAM carriage preva g with human immun g items such as watch S.	lence estimate of the r odeficiency virus, CI: ı, radio, bank account,	eference category fron confidence intervals, y iron (charcoal), sewing	n the comparator categ y: year, SES: Social Eo g machine (electric), r	gory and then dividing conomic Status score b nobile phone, CD play	the absolute difference ased a possession inde er, fan (electric), bedne	by the reference cate x which is calculated at, mattress, bed, bicyc	gory then multiplied b as a sum of positive re cle, motorcycle, car, an	y 100%. sponses for housel nd television. Midc
211			4.8 (-20.9, 13.5) 21.9 (1.6, 43.7) 11.5 (-6.7, 31.5) 9.7 (-0.8, 29.1) 3.6 (-64,9, 53.7) 5.0 (-61.0, 91.2) 0.0 (-55.1, 77.4) 1 (-40.9, 142.5) d by subtracting a /HIV: adults living fferent functioning named as high SE	4.8 (-20.9, 13.5) -18.1 (-35.7, 1.7) 21.9 (1.6, 43.7) 41.8 (12.5, 74.0) 11.5 (-6.7, 31.5) 1.9 (-20.8, 28.4) 9.7 (-0.8, 29.1) 27.2 (0.4, 57.4) 8.6 (-64,9, 53.7) -16.6 (-51.2, 28.6) 5.0 (-61.0, 91.2) -26.5 (-67.6, 19.6) 0.0 (-55.1, 77.4) -14.5 (-49.6, 32.3) 1 (-40.9, 142.5) -40.2 (-64.7, -9.9) d by subtracting a GAM carriage preval/HIV: adults living with human immun fferent functioning items such as watch named as high SES.	1.8 (-20.9, 13.5) -18.1 (-35.7, 1.7) 16.3 (-15.9, 57.2) 21.9 (1.6, 43.7) 41.8 (12.5, 74.0) 2.1 (-26.0, 32.9) 11.5 (-6.7, 31.5) 1.9 (-20.8, 28.4) 4.7 (-23.9, 40.6) 9.7 (-0.8, 29.1) 27.2 (0.4, 57.4) 2.6 (-22.9, 31.8) 8.6 (-64,9, 53.7) -16.6 (-51.2, 28.6) 26.8 (-42.8, 146.6) 5.0 (-61.0, 91.2) -26.5 (-67.6, 19.6) 12.5 (-46.6, 85.4) 0.0 (-55.1, 77.4) -14.5 (-49.6, 32.3) -15.3 (-63.7, 65.3) 1 (-40.9, 142.5) -40.2 (-64.7, -9.9) -6.6 (-52.3, 54.3) d by subtracting a GAM carriage prevalence estimate of the r 'HIV: adults living with human immunodeficiency virus, CI: fferent functioning items such as watch, radio, bank account, named as high SES.	1.8 (-20.9, 13.5) -18.1 (-35.7, 1.7) 16.3 (-15.9, 57.2) 19.0 (-8.5, 52.9) 21.9 (1.6, 43.7) 41.8 (12.5, 74.0) 2.1 (-26.0, 32.9) 22.2 (-2.8, 49.2) 11.5 (-6.7, 31.5) 1.9 (-20.8, 28.4) 4.7 (-23.9, 40.6) 4.4 (-15.7, 26.8) 9.7 (-0.8, 29.1) 27.2 (0.4, 57.4) 2.6 (-22.9, 31.8) 0.3 (-19.5, 22.1) 3.6 (-64,9, 53.7) -16.6 (-51.2, 28.6) 26.8 (-42.8, 146.6) -5.1 (-47.8, 59.1) 5.0 (-61.0, 91.2) -26.5 (-67.6, 19.6) 12.5 (-46.6, 85.4) 23.8 (-32.4, 90.8) 0.0 (-55.1, 77.4) -14.5 (-49.6, 32.3) -15.3 (-63.7, 65.3) 33.7 (-19.3, 102.1) 1 (-40.9, 142.5) -40.2 (-64.7, -9.9) -6.6 (-52.3, 54.3) 8.6 (-36.6, 67.6) d by subtracting a GAM carriage prevalence estimate of the reference category from three	1.8 (-20.9, 13.5) -18.1 (-35.7, 1.7) 16.3 (-15.9, 57.2) 19.0 (-8.5, 52.9) -10.3 (-25.5, 6.8) 21.9 (1.6, 43.7) 41.8 (12.5, 74.0) 2.1 (-26.0, 32.9) 22.2 (-2.8, 49.2) 19.9 (-1.8, 42.9) 11.5 (-6.7, 31.5) 1.9 (-20.8, 28.4) 4.7 (-23.9, 40.6) 4.4 (-15.7, 26.8) 19.9 (-0.4, 41.8) 9.7 (-0.8, 29.1) 27.2 (0.4, 57.4) 2.6 (-22.9, 31.8) 0.3 (-19.5, 22.1) 8.9 (-9.2, 28.5) 3.6 (-64.9, 53.7) -16.6 (-51.2, 28.6) 26.8 (-42.8, 146.6) -5.1 (-47.8, 59.1) -33.3 (-55.6, -5.8) 5.0 (-61.0, 91.2) -26.5 (-67.6, 19.6) 12.5 (-46.6, 85.4) 23.8 (-32.4, 90.8) 35.8 (-14.5, 93.2) 0.0 (-55.1, 77.4) -14.5 (-49.6, 32.3) -15.3 (-63.7, 65.3) 33.7 (-19.3, 102.1) -2.9 (-36.4, 35.0) 1 (-40.9, 142.5) -40.2 (-64.7, -9.9) -6.6 (-52.3, 54.3) 8.6 (-36.6, 67.6) -29.1 (-52.8, -0.5) d by subtracting a GAM carriage prevalence estimate of the reference category from the comparator categor HIV: adults living with human immunodeficiency virus, CI: confidence intervals, y: year, SES: Social Ex fferent functioning items such as watch, radio, bank account, iron (charcoal), sewing machine (electric), mamed as high SES. 14.8 (-14.7, -14.5, -14.5, -14.5, -14.5, -14.5, -14.5, -14.5, -14.5, -14.5, -14.5, -14.5, -14.5, -14.5, -14.5, -14.5, -14.	1.8 (-20.9, 13.5) -18.1 (-35.7, 1.7) 16.3 (-15.9, 57.2) 19.0 (-8.5, 52.9) -10.3 (-25.5, 6.8) -13.5 (-35.5, 12.7) 21.9 (1.6, 43.7) 41.8 (12.5, 74.0) 2.1 (-26.0, 32.9) 22.2 (-2.8, 49.2) 19.9 (-1.8, 42.9) 16.5 (-16.2, 52.2) 11.5 (-6.7, 31.5) 1.9 (-20.8, 28.4) 4.7 (-23.9, 40.6) 4.4 (-15.7, 26.8) 19.9 (-0.4, 41.8) 35.4 (0.9, 77.2) 9.7 (-0.8, 29.1) 27.2 (0.4, 57.4) 2.6 (-22.9, 31.8) 0.3 (-19.5, 22.1) 8.9 (-9.2, 28.5) 8.7 (-18.4, 39.5) 3.6 (-64.9, 53.7) -16.6 (-51.2, 28.6) 26.8 (-42.8, 146.6) -5.1 (-47.8, 59.1) -33.3 (-55.6, -5.8) -21.4 (-58.3, 31.3) 5.0 (-61.0, 91.2) -26.5 (-67.6, 19.6) 12.5 (-46.6, 85.4) 23.8 (-32.4, 90.8) 35.8 (-14.5, 93.2) 17.7 (-47.0, 94.6) 0.0 (-55.1, 77.4) -14.5 (-49.6, 32.3) -15.3 (-63.7, 65.3) 33.7 (-19.3, 102.1) -2.9 (-36.4, 35.0) 32.7 (-26.2, 114.5) 1 (-40.9, 142.5) -40.2 (-64.7, -9.9) -6.6 (-52.3, 54.3) 8.6 (-36.6, 67.6) -29.1 (-52.8, -0.5) 7.7 (-43.3, 73.9) d by subtracting a GAM carriage prevalence estimate of the reference category from the comparator category and then dividing 'HIV: adults living with human immunodeficiency virus, CI: confidence intervals, y: year, S	18.1 (-20.9, 13.5) -18.1 (-35.7, 1.7) 16.3 (-15.9, 7.2) 19.0 (-8.5, 52.9) -10.3 (-25.5, 6.8) -13.5 (-3.5, 51.2, 7) -6.1 (-23.9, 14.2) 21.9 (1.6, 43.7) 41.8 (12.5, 74.0) 2.1 (-26.0, 32.9) 22.2 (-2.8, 49.2) 19.9 (-1.8, 42.9) 16.5 (-16.2, 52.2) 19.3 (-5.4, 45.8) 11.5 (-6.7, 31.5) 1.9 (-20.8, 28.4) 4.7 (-23.9, 40.6) 4.4 (-15.7, 26.8) 19.9 (-0.4, 41.8) 35.4 (0.9, 77.2) 3.9 (-17.2, 72.5) 9.7 (-0.8, 29.1) 27.2 (0.4, 57.4) 2.6 (-22.9, 31.8) 0.3 (-10.5, 22.1) 8.9 (-9.2, 28.5) 8.7 (-18.4, 39.5) 1.1 (-17.9, 22.2) 9.7 (-0.8, 51.7, 74) 2.6 (-2.8, 74.8) 23.8 (-32.4, 90.8) 35.8 (-14.5, 53.3) 1.8 (-8.4, 74.9) 1.6 (-51.7, 74.9) 1.6 (-42.9, 36.2) 1.7 (-43.3, 73.9) 26.9 (-42.9, 36.2) 1.4 (-43.3, 73.9) 26.9 (-21.2, 89.1) 1.4 (-49.142.5) -6.9	18.1 (-20.9, 13.5) -18.1 (-35.7, 17.7) 16.3 (-15.9, 57.2) 19.0 (-8.5, 52.9) -10.3 (-25.5, 6.8) -13.5 (-3.5, 5.1, 2.7) -6.1 (-23.9, 14.2) 7.1 (-14.5, 32.5) 21.9 (16, 43.7) 41.8 (12.5, 74.0) 2.1 (-26.0, 32.9) 22.2 (-2.8, 49.2) 19.9 (-1.8, 42.9) 16.5 (-16.2, 52.2) 19.3 (-5.4, 45.8) 26.7 (-0.1, 55.2) 11.5 (-6.7, 31.5) 1.9 (-20.8, 28.4) 4.7 (-23.9, 40.6) 4.4 (-15.7, 26.8) 19.9 (-4.4, 41.8) 35.4 (0.9, 77.2) 3.9 (-15.7, 25.3) -0.7 (-19.4, 19.9) 9.7 (-0.8, 29.1) 27.2 (0.4, 57.4) 2.6 (-22.9, 31.8) 0.3 (-19.5, 22.1) 8.9 (-2.2, 2.8.5) 8.7 (-14.7, 8.3.3) 11.1 (-17.9, 22.2) 7.4 (-12.4, 2.9.4) 3.6 (-64.9, 53.7) -16.6 (-51.2, 28.6) 26.8 (-42.8, 146.6) 5.1 (-47.8, 59.1) -33.3 (-55.6, -5.8) -21.4 (-58.3, 31.3) -18.0 (-48.9, 22.5) -13.3 (-47.6, 33.1) 1.6	18.1 (209, 13.5) -18.1 (35.7, 1.7) 16.3 (15.9, 57.2) 19.0 (8.5, 52.9) -10.3 (25.5, 6.8) -13.5 (35.5, 12.7) -6.1 (23.9, 14.2) 7.1 (14.5, 32.5) -12.9 (33.8, 12.2) 21.9 (16, 43.7) 41.8 (12.5, 74.0) 2.1 (26.0, 32.9) 22.2 (2.8, 49.2) 19.9 (-1.8, 42.9) 16.5 (-16.2, 52.2) 19.3 (5.4, 45.8) 26.7 (-0.1, 55.2) 49.5 (13.4, 89.8) 11.5 (-6.7, 31.5) 19 (-20.8, 28.4) 4.7 (23.9, 40.6) 4.4 (-15.7, 26.8) 19.9 (-0.4, 41.8) 35.4 (0.9, 77.2) 3.9 (-15.7, 25.3) -0.7 (-19.4, 19.9) 26.2 (-4.1, 61.4) 9.7 (0.8, 29.1) 27.2 (0.4, 57.4) 2.6 (-22.9, 31.8) 0.3 (-19.5, 22.1) 8.9 (-9.2, 28.5) 8.7 (-18.4, 39.5) 1.1 (17.9, 22.2) 7.4 (-12.4, 29.4) 13.8 (-14.3, 44.7) 9.7 (0.8, 29.1) 2.6 (-22.9, 31.8) 0.3 (-19.5, 22.1) 8.9 (-9.2, 28.5) 8.7 (-18.4, 39.5) 1.1 (17.9, 22.2) 7.4 (-12.4, 29.4) 13.8 (-14.3, 44.7) 9.7 (0.8, 29.1) 2.6 (-22.9, 31.8) 0.3 (-19.5, 22.1) 8.9 (-9.2, 28.5) 8.7 (-18.4, 39.5) 1.1 (17.9, 22.2) 7.4 (-12.4, 29.4) 13.8 (-14.3, 44.7) 9.7 (0.8, 29.1) -2.6 (-64.9, 6.3) 1.3 (-3.7, 65.3) 3.7 (-19.3, 192.1) -2.9 (-14.6 (-53.3, 31.3) 1.1 (-54.9, 27.3) <t< td=""></t<>



278

279 Figure 3. P-spline generalised additive model: Observed and fitted pneumococcal carriage prevalence 280 curves for each potential risk factor category using data from rolling, prospective cross-sectional 281 surveys in Blantyre, Malawi 2015-19. Nasopharyngeal samples across age groups from 18 to 40 years 282 (y) and time represented by open circles. Circle radius is proportional to total sample size with 283 corresponding confidence intervals (vertical lines). The coloured lines show P-spline GAM fitted 284 model and confidence intervals for age- and time-dependent carriage prevalence for overall carriage 285 (plots from first row) and vaccine serotypes (VT) carriage (plots from second row) stratified by risk 286 factor categories.

288 Discussion

289	We used generalised additive models to estimate age- and time-dependent overall (VT+NVT) and VT $\!\!\!$
290	pneumococcal carriage prevalence and related risk factors in ALWHIV on ART. We analysed overall
291	and VT carriage separately to take into account the effect of a high uptake infant PCV13 programme
292	⁴² . Overall and VT carriage declined with increasing age group and time, with VT carriage having a
293	faster decline (faster still if serotype 3 was excluded from VT). Our models predicted higher overall
294	carriage prevalence in younger adults from low SES and living with a child <5y, as well as those with
295	shorter duration on ART. Conversely, VT carriage prevalence was predominantly high in older males,
296	and younger and older adults not living with a child <5y. These findings suggest that the decline in
297	VT carriage prevalence across time in ALWHIV on ART is in part due to VT indirect protection from
298	vaccinated younger children, although it is imperfect in males or adults not living with younger
299	children, who may potentially have different routes of pneumococcal acquisition outside the
300	household. Reduction in overall carriage suggests a combined effect of infant PCV13 vaccination and
301	widespread use of antibiotics (i.e. cotrimoxazole) among adults in this setting.
302	
303	Our analysis of risk factors for persistent carriage in ALWHIV on ART in the post PCV13
304	introduction era in urban Blantyre extends our previous observations that focussed mainly on high
305	residual VT carriage and its determinants in PCV13-vaccinated and unvaccinated children ^{15,16} . We
306	now show substantially high overall and VT carriage prevalence in ALWHIV during the earlier (45%
307	and 17%) than later (28% and 7%) years post infant-PCV13 introduction. VT carriage declined faster
308	than overall carriage, suggesting cumulative vaccine-induced community-level indirect protection
309	from infant PCV vaccination ^{43–45} . The temporal reduction in VT carriage prevalence was even more
310	marked when serotype 3 was excluded (and included as NVT), supporting accumulating evidence of
311	the reduced effectiveness of PCV13 against serotype 3 ^{36,37} .

312

313 Higher overall and VT carriage prevalences among younger than older adults reported in this study

314 may suggest distinct high carriage acquisition risk in younger adults, partly supported by recent

315 evidence of higher rates of skin-to-skin contacts between younger adults and with other age groups in

16

316	urban Blantyre ⁴⁶ . The shorter median duration on ART amongst the younger adults as shown in S6
317	Fig may contribute to this residual pneumococcal carriage through incomplete immune reconstitution
318	at both the systemic and mucosal level ^{27,47,48} .
319	
320	Low SES neighbourhoods in urban Blantyre predominantly comprise high-density informal
321	settlements, relatively larger households and low rates of formal employment ²⁸ . Thus, substantial
322	overall carriage prevalence in younger adults from low SES suggests that factors associated with low
323	SES such as poorly ventilated and overcrowded houses with intense social contacts are reservoirs for
324	pneumococcal carriage in the PCV13 era ^{16,28,46,49} . On the contrary, non-differential VT carriage
325	prevalence by household SES underlines an important role PCV vaccination plays to outweigh
326	infection risks in poor settings. We uncover a phenomenon where adults living with children <5y,
327	mostly PCV13 recipients given the high (>90%) infant PCV13 vaccination coverage ¹⁵ , have
328	substantially lower VT but higher overall carriage prevalence suggesting some non-vaccine serotype
329	(NVT) replacement in adults within households, in line with evidence from rural Malawi and South
330	Africa ^{50,51} .
331	
332	In this setting, VT carriage prevalence was higher in older male than female adults. VT carriage
333	acquisition between mothers and their infants has been demonstrated previously in Malawi and South
334	Africa prior to infant-PCV introduction ^{20,21} . Thus, our finding aligns with recent evidence in the same
335	setting showing strong intergenerational social mixing patterns between females and their potentially
336	PCV13-vaccinated younger children likely through parental or guardian roles ⁴⁶ . This suggests that in
337	the infant-PCV13 era, interruption of VT carriage transmission likely favors females than males.

338

339 Overall and VT carriage prevalence in ALWHIV on ART are heterogenous by age such that

340 epidemiological models for carriage that incorporate ALWHIV should stratify for age for precise

341 estimations. Our findings have policy implications in sub-Saharan African populations affected by

342 HIV as persistent VT carriage in ALWHIV may imply continued risk of VT-IPD¹⁴. The indirect

343 impact on VT carriage of alternative infant-PCV13 vaccine strategies, including 2 primary doses with

344	a booster dose or double booster doses (i.e. 2+1 or 2+1+1), currently being tested to improve the
345	control of childhood disease, should also be further evaluated in ALWHIV ¹⁸ . Indeed the 2+1
346	schedule, as implemented in South Africa, has generated indirect protection against IPD in
347	unvaccinated older children and ALWHIV ^{44,52} . However, simply improving control of carriage in
348	young children to indirectly protect vunerable immunocompromised adults may be insufficient,
349	particularly in the context of a high local force of infection and a rapid waning of vaccine-induced
350	immunity ^{16,53} . Furthermore, we provide evidence of heterogeneity in VT carriage prevalence with
351	males or adults living without <5y child in their homes being at highest risk of VT carriage in the
352	PCV era. Together, these data add weight to our viewpoint that as with many people living in high-
353	income countries, targeted-pneumococcal vaccination should be considered in ALWHIV in LMICs.
354	
355	We used a robust dataset with adequate samples to compute estimates for the overall, VT and risk
356	factor-dependent carriage prevalence. Nonetheless, there were some limitations to our work, including
357	limited data on risk factors such as viral load, use of tobacco, presence of other chronic co-
358	morbidities, adherence to ART and history of antibiotics, which may independently influence carriage
359	dynamics ⁵⁴ . In addition, latex agglutination method used in the main analysis for single serotype
360	detection could underestimate our current prevalence estimates as compared to a more sensitive
361	microarray method for multiple serotype detection as show in S2 Fig. Finally, the systematic
362	recruitment of ALWHIV may be prone to bias if a cyclical pattern (unnoticeable here) is present in
363	the important characteristics of the individuals as they attend the ART clinic ⁵⁵ .
364	
365	In conclusion, despite temporal reductions in overall pneumococcal carriage, the risk of VT carriage
366	and therefore subsequent pneumococcal disease remains high in ALWHIV. Efficient infant PCV
367	schedules that enhance indirect protection together with targeted-vaccination for ALWHIV should be
368	considered, along with other public health measures to further reduce VT carriage and disease. These
369	measures should be supported by robust surveillance to assess effectiveness and identify early
370	evidence of vaccine escape.

18

371 Acknowledgements

372 We thank the individuals who participated in this study and the local authorities for their support. We 373 are grateful to the study field teams (supported by Farouck Bonomali and Roseline Nyirenda). We are 374 grateful to the hospitality of the QECH ART Clinic, led by Ken Malisita. Our thanks also extend to 375 the MLW laboratory management team (led by Brigitte Denis) and the MLW data management team 376 (led by the late Clemens Masesa whose contribution we wish to particularly acknowledge). DT, KCJ, 377 JO, SF NF, RSH, and TDS are supported by the National Institute for Health and Care Research 378 (NIHR) Global Health Research Unit on Mucosal Pathogens and RSH is a NIHR Senior Investigator. 379 The views expressed in this publication are those of the authors and not necessarily those of the NIHR 380 or the Department of Health and Social Care. The MLW Programme is supported by a Strategic 381 Award from the Wellcome, UK

382 Author contributions

- 383 Conceptualization; DT, SF, NF, TDS, RSH
- 384 Data curation; DT, TDS, TM
- 385 Formal analysis; DT, SF
- 386 Funding acquisition; NF, RSH, TDS
- 387 Investigation; DT, TM, AK, JM, CB, TDS
- 388 Methodology; DT, SF
- 389 Project administration; TM, AK, JM, CB, CM, NF, RSH, TDS
- 390 Resources; NF, RSH, TDS
- 391 Software; DT
- 392 Supervision; SF, NF, KCJ, TDS
- 393 Validation; DT, TM, KCJ, AK, JM, CB, CM, JO, SF, NF, RSH, TDS
- 394 Visualization; DT
- 395 Writing original draft; DT
- 396 Writing review & editing; DT, TM, KCJ, AK, JM, CB, CM, JO, SF, NF, RSH, TDS
- 397 All authors read and approved the final manuscript.

19

398

Data availability

400 An R script that was used to analyse the datasets is available in the GitHub repository ⁴¹.

401

402 **Competing interests**

403 The authors declare no competing interests.

404

405 **Role of the funding source**

406 A project grant jointly funded by the UK Medical Research Council (MRC) and the UK Department 407 for International Development (DFID) under the MRC/DFID Concordat agreement, also as part of the 408 EDCTP2 programme supported by the European Union (Grant MR/N023129/1); and a recruitment 409 award from the Wellcome (Grant 106846/Z/15/Z). The MLW Programme is supported by a Strategic 410 Award from the Wellcome, UK. The National Institute for Health and Care Research (NIHR) Global 411 Health Research Unit on Mucosal Pathogens is supported using UK aid from the UK Government 412 (Grant 16/136/46). SF is also supported by a Sir Henry Dale Fellowship jointly funded by the 413 Wellcome Trust and the Royal Society (Grant 208812/Z/17/Z). The views expressed in this 414 publication are those of the author(s) and not necessarily those of the NIHR or the Department of 415 Health and Social Care. The funders had no role in study design, collection, analysis, data 416 interpretation, writing of the report or in the decision to submit the paper for publication. The 417 corresponding author and senior authors had full access to the study data, and together, had final 418 responsibility for the decision to submit for publication.

20

420 **References**

- 421 1. WHO. WHO Pneumococcus vaccines position paper. 85–104
- 422 https://www.who.int/immunization/policy/position_papers/pneumococcus/en/ (2019).
- 423 2. Simell, B. *et al.* The fundamental link between pneumococcal carriage and disease. *Expert*424 *Review of Vaccines* 11, 841–855 (2012).
- 425 3. Bar-Zeev, N., Mtunthama, N., Gordon, S. B., Mwafulirwa, G. & French, N. Minimum Incidence
- 426 of Adult Invasive Pneumococcal Disease in Blantyre, Malawi an Urban African Setting: A
- 427 Hospital Based Prospective Cohort Study. *PLOS ONE* **10**, e0128738 (2015).
- 428 4. Meiring, S. *et al.* HIV Infection and the Epidemiology of Invasive Pneumococcal Disease (IPD)
 429 in South African Adults and Older Children Prior to the Introduction of a Pneumococcal
- 430 Conjugate Vaccine (PCV). *PLOS ONE* **11**, e0149104 (2016).
- 431 5. Corcoran, M. *et al.* The epidemiology of invasive pneumococcal disease in older adults in the
 432 post-PCV era. Has there been a herd effect? *Epidemiology & Infection* 145, 2390–2399 (2017).
- 433 6. Dwyer-Lindgren, L. *et al.* Mapping HIV prevalence in sub-Saharan Africa between 2000 and
 434 2017. *Nature* 570, 189 (2019).
- 435 7. Frank, T. D. et al. Global, regional, and national incidence, prevalence, and mortality of HIV,
- 436 1980–2017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the
- Global Burden of Diseases, Injuries, and Risk Factors Study 2017. *The Lancet HIV* 6, e831–e859
 (2019).
- 439 8. Choko, A. T. *et al.* Uptake, Accuracy, Safety, and Linkage into Care over Two Years of
 440 Promoting Annual Self-Testing for HIV in Blantyre, Malawi: A Community-Based Prospective
 441 Study. *PLOS Medicine* 12, e1001873 (2015).
- 442 9. van Aalst, M. *et al.* Incidence of invasive pneumococcal disease in immunocompromised
 443 patients: A systematic review and meta-analysis. *Travel Medicine and Infectious Disease* 24, 89–
 444 100 (2018).
- Harries, A., Makombe, S., Libamba, E. & Schouten, E. Why Did the Scale-up of HIV Treatment
 Work?: A Case Example From Malawi. *Jaids Journal of Acquired Immune Deficiency Syndromes*57, (2011).

- 448 11. Harries, A. D. et al. Act local, think global: how the Malawi experience of scaling up
- antiretroviral treatment has informed global policy. *BMC Public Health* **16**, 938 (2016).
- 450 12. Jahn, A. et al. Scaling-up antiretroviral therapy in Malawi. Bulletin of the World Health
- 451 *Organization* **94**, 772–776 (2016).
- 452 13. VACFA. Immunization Schedules Africa | Vaccines for Africa.
 453 http://www.vacfa.uct.ac.za/immunization-schedules-africa (2018).
- 454 14. Bar-Zeev, N. et al. Impact and effectiveness of 13-valent pneumococcal conjugate vaccine on
- 455 population incidence of vaccine and non-vaccine serotype invasive pneumococcal disease in
- 456 Blantyre, Malawi, 2006–18: prospective observational time-series and case-control studies. *The*
- 457 *Lancet Global Health* **9**, e989–e998 (2021).
- 458 15. Swarthout, T. D. et al. High residual carriage of vaccine-serotype Streptococcus pneumoniae after
- 459 introduction of pneumococcal conjugate vaccine in Malawi. *Nature Communications* 11, 2222
 460 (2020).
- 461 16. Lourenço, J. *et al.* Determinants of high residual post-PCV13 pneumococcal vaccine-type
 462 carriage in Blantyre, Malawi: a modelling study. *BMC Medicine* 17, (2019).
- 463 17. Klugman, K. P. & Rodgers, G. L. Population versus individual protection by pneumococcal
 464 conjugate vaccination. *The Lancet* 393, 2102–2104 (2019).
- 18. Thindwa, D. *et al.* Vaccine strategies to reduce the burden of pneumococcal disease in HIVinfected adults in Africa. *Expert Review of Vaccines* 0, 1–8 (2020).
- 467 19. WHO | Pneumococcal conjugate 3rd dose (PCV3) immunization coverage. WHO
 468 http://www.who.int/gho/immunization/pneumococcal/en/ (2019).
- 469 20. Shiri, T. et al. Dynamics of Pneumococcal Transmission in Vaccine-Naïve Children and Their
- 470 HIV-infected or HIV-uninfected Mothers During the First 2 Years of Life. Am J Epidemiol 178,
- 471 1629–1637 (2013).
- 472 21. Heinsbroek, E. *et al.* Pneumococcal Acquisition Among Infants Exposed to HIV in Rural
 473 Malawi: A Longitudinal Household Study. *Am J Epidemiol* 183, 70–78 (2016).

- 474 22. le Polain de Waroux, O. et al. Characteristics of human encounters and social mixing patterns
- 475 relevant to infectious diseases spread by close contact: a survey in Southwest Uganda. BMC
- 476 *Infectious Diseases* **18**, 172 (2018).
- 477 23. le Polain de Waroux, O. et al. Identifying human encounters that shape the transmission of
- 478 Streptococcus pneumoniae and other acute respiratory infections. *Epidemics* **25**, 72–79 (2018).
- 479 24. Neal, E. F. G. et al. Factors associated with pneumococcal carriage and density in children and
- 480 adults in Fiji, using four cross-sectional surveys. *PLOS ONE* **15**, e0231041 (2020).
- 481 25. Neal, E. F. G. et al. Associations between ethnicity, social contact, and pneumococcal carriage
- 482 three years post-PCV10 in Fiji. *Vaccine* **38**, 202–211 (2020).
- 483 26. Heinsbroek, E. *et al.* Persisting high prevalence of pneumococcal carriage among HIV-infected
 484 adults receiving antiretroviral therapy in Malawi. *Aids* 29, 1837–1844 (2015).
- 485 27. Glennie, S. J. et al. Defective Pneumococcal-Specific Th1 Responses in HIV-Infected Adults
- 486 Precedes a Loss of Control of Pneumococcal Colonization. *Clin Infect Dis* **56**, 291–299 (2013).
- 487 28. National Statistical Office Malawi. Malawi Population and Housing Census 2018. 1-311
- 488 http://www.nsomalawi.mw/index.php%3Foption%3Dcom_content%26view%3Darticle%26id%3
- 489 D226:2018-malawi-population-and-housing-
- 490 census%26catid%E2%80%89%3D%E2%80%898:reports%26Itemid%E2%80%89%3D%E2%80
 491 %896 (2019).
- 492 29. Ministry of Health. *Malawi Guidelines for Clinical Management of HIV in Children and Adults*.
 493 1–128
- 494 https://differentiatedservicedelivery.org/Portals/0/adam/Content/yb4xSSLvE0SW98_z7wTm_w/
 495 File/Malawi%20Clinical%20HIV%20Guidelines%202018%20(1).pdf (2018).
- 496 30. Satzke, C. et al. Standard method for detecting upper respiratory carriage of Streptococcus
- 497 pneumoniae: Updated recommendations from the World Health Organization Pneumococcal
- 498 Carriage Working Group. *Vaccine* **32**, 165–179 (2013).
- 31. Newton, R., Hinds, J. & Wernisch, L. Empirical Bayesian models for analysing molecular
 serotyping microarrays. *BMC Bioinformatics* 12, 88 (2011).

- 501 32. Swarthout, T. D. et al. Evaluation of Pneumococcal Serotyping of Nasopharyngeal-Carriage
- 502 Isolates by Latex Agglutination, Whole-Genome Sequencing (PneumoCaT), and DNA
- 503 Microarray in a High-Pneumococcal-Carriage-Prevalence Population in Malawi. Journal of

504 *Clinical Microbiology* **59**, (2020).

- 505 33. Kamng'ona, A. W. *et al.* High multiple carriage and emergence of Streptococcus pneumoniae
- 506 vaccine serotype variants in Malawian children. *BMC Infectious Diseases* **15**, 234 (2015).
- 507 34. Stekhoven, D. J. & Bühlmann, P. MissForest—non-parametric missing value imputation for
 508 mixed-type data. *Bioinformatics* 28, 112–118 (2012).
- 509 35. Eilers, P. H. C. & Marx, B. D. Flexible Smoothing with B-splines and Penalties. *Statistical*510 *Science* 11, 89–102 (1996).
- 511 36. Linley, E., Bell, A., Gritzfeld, J. F. & Borrow, R. Should Pneumococcal Serotype 3 Be Included
 512 in Serotype-Specific Immunoassays? *Vaccines* 7, 4 (2019).
- 513 37. Usuf, E. et al. Persistence of Nasopharyngeal Pneumococcal Vaccine Serotypes and Increase of
- 514 Nonvaccine Serotypes Among Vaccinated Infants and Their Mothers 5 Years After Introduction
- 515 of Pneumococcal Conjugate Vaccine 13 in The Gambia. *Clin Infect Dis* 68, 1512–1521 (2019).
- 516 38. Hens, N. et al. Modeling Infectious Disease Parameters Based on Serological and Social Contact
- 517 Data: A Modern Statistical Perspective. (Springer Science & Business Media, 2012).
- 518 39. Kohavi, R., Longbotham, R., Sommerfield, D. & Henne, R. M. Controlled experiments on the
- 519 web: survey and practical guide. *Data Min Knowl Disc* **18**, 140–181 (2009).
- 40. R Core Team (2018). R: A language and environment for statistical computing. R Foundation for
 Statistical Computing, Vienna, Austria. https://www.r-project.org/.
- 522 41. Thindwa, D. R code and data for Age- and time-dependent risk factors for pneumococcal carriage
- 523 in HIV-positive adults on ART in the infant PCV era in Blantyre, Malawi.
- 524 https://github.com/deusthindwa/Pneumo.carriage.adults.hiv.malawi (2021).
- 525 42. Mvula, H. et al. Predictors of Uptake and Timeliness of Newly Introduced Pneumococcal and
- 526 Rotavirus Vaccines, and of Measles Vaccine in Rural Malawi: A Population Cohort Study. PLOS
- 527 *ONE* **11**, e0154997 (2016).

528	43. Nzenze,	S. A. N	1. C. et al.	Temporal	Changes	in Pneumococcal	Colonization	in a Rural African
-----	-------------	---------	--------------	----------	---------	-----------------	--------------	--------------------

- 529 Community With High HIV Prevalence Following Routine Infant Pneumococcal Immunization.
- 530 *Journal* **32**, 1270–1278 (2013).
- 531 44. Nzenze, S. A. et al. Imputing the Direct and Indirect Effectiveness of Childhood Pneumococcal
- 532 Conjugate Vaccine Against Invasive Pneumococcal Disease by Surveying Temporal Changes in
- 533 Nasopharyngeal Pneumococcal Colonization. *Am J Epidemiol* **186**, 435–444 (2017).
- 45. Roca, A. *et al.* Effects of Community-Wide Vaccination with PCV-7 on Pneumococcal
 Nasopharyngeal Carriage in The Gambia: A Cluster-Randomized Trial. *PLOS Medicine* 8,
 e1001107 (2011).
- 53746. Thindwa, D. et al. Social mixing patterns relevant to infectious diseases spread by close contact538inurbanBlantyre,Malawi.2021.12.16.21267959
- 539 https://www.medrxiv.org/content/10.1101/2021.12.16.21267959v1 (2021)
- 540 doi:10.1101/2021.12.16.21267959.
- 47. Glennie, S. J. *et al.* Impaired CD4 T cell memory response to Streptococcus pneumoniae precedes
 CD4 T cell depletion in HIV-infected Malawian adults. *PLoS ONE* 6, e25610 (2011).
- 543 48. Zhang, L. et al. Humoral immune responses to Streptococcus pneumoniae in the setting of HIV-1
- 544 infection. *Vaccine* **33**, 4430–4436 (2015).
- 545 49. Dherani, M., Heinsbroek, E., Tafatatha, T., Chartier, R. & Bruce, N. Household Air Pollution and
 546 Pneumococcal Carriage in 6 Months Old Children in Malawi MSCAPE Study. *ISEE*547 *Conference Abstracts* (2018) doi:10.1289/isee.2017.2017-558.
- 548 50. Heinsbroek, E. *et al.* Pneumococcal carriage in households in Karonga District, Malawi, before 549 and after introduction of 13-valent pneumococcal conjugate vaccination. *Vaccine* **36**, 7369–7376 550 (2018)
- 550 (2018).
- 551 51. Cohen, C. et al. Effectiveness of the 13-valent pneumococcal conjugate vaccine against invasive
- pneumococcal disease in South African children: a case-control study. *The Lancet Global Health*5, e359–e369 (2017).

- 554 52. Madhi, S. A. & Nunes, M. C. The potential impact of pneumococcal conjugate vaccine in Africa:
- 555 Considerations and early lessons learned from the South African experience. *Human Vaccines &*
- 556 *Immunotherapeutics* **12**, 314–325 (2016).
- 557 53. Flasche, S., Lipsitch, M., Ojal, J. & Pinsent, A. Estimating the contribution of different age strata
- to vaccine serotype pneumococcal transmission in the pre vaccine era: a modelling study. BMC
- 559 *Medicine* **18**, (2020).
- 560 54. Thindwa, D. et al. Estimating the contribution of HIV-infected adults to household pneumococcal
- 561 transmission in South Africa, 2016–2018: A hidden Markov modelling study. *PLOS*
- 562 *Computational Biology* **17**, e1009680 (2021).
- 563 55. PHAST. Methods of sampling from a population. *Health Knowledge*564 https://www.healthknowledge.org.uk/public-health-textbook/research-methods/1a-
- 565 epidemiology/methods-of-sampling-population (2010).
- 566